Coronary in-stent restenosis - predictors, treatment and prevention.
about
Indirubin and Indirubin Derivatives for Counteracting Proliferative DiseasesCompound ex vivo and in silico method for hemodynamic analysis of stented arteriesRationale and study design of the CardioGene Study: genomics of in-stent restenosis.Association between VEGF Gene Polymorphisms and In-Stent Restenosis after Coronary Intervention Treated with Bare Metal Stent.Promoting endothelial recovery and reducing neointimal hyperplasia using sequential-like release of acetylsalicylic acid and paclitaxel-loaded biodegradable stentsLeukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia.Cost-effectiveness of drug-eluting vs. bare-metal stents in patients with coronary artery disease from the Korean National Health Insurance DatabaseDevelopment and characterization of a coronary polylactic acid stent prototype generated by selective laser melting.Real world experience with an indigenously manufactured stent Cobal C--a retrospective study.Effectiveness of drug-eluting stents versus bare-metal stents in large coronary arteries in patients with acute myocardial infarction.Bioresorbable polymeric stents: current status and future promise.Sry-type HMG box 18 contributes to the differentiation of bone marrow-derived mesenchymal stem cells to endothelial cells.Pharmacological treatment for prevention of restenosis.High rate of in-stent restenosis after coronary intervention in carriers of the mutant mannose-binding lectin allele.Tissue Kallikrein Prevents Restenosis After Stenting of Severe Atherosclerotic Stenosis of the Middle Cerebral Artery: A Randomized Controlled TrialLeukotriene receptors in atherosclerosis.Association of a unique cardiovascular risk profile with outcomes in Hispanic patients referred for percutaneous coronary intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry).Percutaneous coronary intervention using a full metal jacket with drug-eluting stents: major adverse cardiac events at one year.5 Years Experience With Drug Eluting and Bare Metal Stents as Primary Intervention in Transplant Renal Artery Stenosis.Long-term effectiveness and safety of sirolimus drug-eluting stents.Perioperative management of antiplatelet therapy in patients with drug-eluting stents.The everolimus-eluting Xience stent in small vessel disease: bench, clinical, and pathology view.Direct stenting versus pre-dilation in ST-elevation myocardial infarction: a systematic review and meta-analysis.Colchicine in cardiovascular disease: an ancient drug with modern tricks.Stainless steel surface functionalization for immobilization of antibody fragments for cardiovascular applications.Feasibility and Efficacy of Herculink Elite ((TM)) Biliary Stent Implantation in Large Coronary Arteries (≥ 5 mm) and Venous Conduits: An Observational Study.Use of fraction flow reserve to predict changes over time in management of superficial femoral artery.Percutaneous revascularization of long femoral artery lesions for claudication: patency over 2.5 years and impact of systematic surveillance.Multi-scale simulations of the dynamics of in-stent restenosis: impact of stent deployment and design.In stent restenosis after percutaneous coronary intervention.Murine model of femoral artery wire injury with implantation of a perivascular drug delivery patch.Plasma levels of interleukin 18, interleukin 10, and matrix metalloproteinase-9 and -137G/C polymorphism of interleukin 18 are associated with incidence of in-stent restenosis after percutaneous coronary intervention.Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels.Perioperative use of dual antiplatelet therapy for patients with coronary artery stents.Vitronectin and Urokinase-Type Plasminogen Activator Gene Expression Levels Are Increased in Patients with Coronary Artery In-Stent Restenosis.Usefulness of the CHA2DS2-VASc Score in Predicting In-Stent Restenosis Among Patients Undergoing Revascularization With Bare-Metal Stents.Coronary in-stent restenosis: predisposing clinical and stent-related factors, diagnostic performance and analyses of inaccuracies in 320-row computed tomography angiography.Cardiac rehabilitation reduces the rate of major adverse cardiac events after percutaneous coronary intervention.Wingspan stenting with modified predilation for symptomatic middle cerebral artery stenosis.Urban legend or real fact: Coronary artery size varies with demographics.
P2860
Q26784341-84E003B4-1599-4B58-87AD-9DE3E54821C7Q27335493-42937890-62B7-41F9-ACA6-F01CEF976168Q31119076-BF4F5B13-D67E-4CF4-8287-C29C7D375E63Q33623845-ACCF6EC9-D891-4E51-9687-A963D77B9F5AQ34148996-3103CEAF-AB3B-4BAB-8185-B9893A99BD91Q34161069-33FF5A2B-A8B4-440A-8161-302DB3656A5CQ34384310-3F331661-B806-43A7-BE7A-32F16CB7DACFQ34440106-70C3F44D-FD0F-4A3D-8EEC-92E834BD3F58Q34466983-04195621-EE58-451E-B0E0-DD58DE7A5425Q34753360-D23DD3A7-4B3A-45C5-AA6C-16ADAB419790Q35127874-A7336DF5-3C4B-47FD-B553-DF53EFBD0520Q35776368-D92390C8-B5FA-42A5-895C-273359844585Q36179679-D89F52AD-A931-4A37-8DB0-121835F74EF6Q36240744-63C92DB4-090B-4B1F-8CB0-1D19200D270BQ36581185-1DB5621C-35AA-41B6-A09C-432B5C9AF150Q36652544-B9BF06C8-84A3-41E0-BA06-0ACABB6B84CDQ37474690-B9ADDD04-D15B-4621-9AE3-45D589C6E521Q37720739-36DC2B06-E1AB-46A1-A8BF-D171D43ECBD1Q37722904-28281363-C061-4A18-B66F-681CC845CCA7Q38037074-AF8AD4FE-E672-4C5D-9895-40E02175C167Q38084549-9503B876-30DC-4D52-9BBD-E08A375FE32EQ38310049-975101DB-44D2-4888-BF93-4486E4F16AA5Q38425962-983A4121-C31A-4D31-BB06-222E24B2E44CQ38780826-78B91901-5A88-4A92-87C3-A4B4FD365537Q38819659-6ECC23A6-810A-4BA4-AA2B-7298CBCCC1A5Q38979678-780503F4-625E-4C05-BDCF-EA46252909BAQ39686029-A590867C-B45B-4A50-8F0E-26DD8388961EQ39836090-A0930DE0-193E-438C-8495-88A196493754Q40543139-4A8DDB33-7A04-4709-906F-6A0A7EC127FAQ42318551-72D6B119-AACB-49C6-A6E4-0959466F2F02Q42557991-A95BE0EB-17E7-4DC7-B388-D9B8F96B2F0FQ44534686-CE51FA1F-A6F9-4379-9963-C6AD6883E7E7Q46886141-77BDCC03-9A66-42A2-850F-6A256BCDCCC2Q48447186-AFF51D27-3CD9-46F7-B1F7-40A74D53B910Q49984918-D1E3FB76-1799-4E07-B7EC-D1575DE059DDQ50908775-F0D15702-65DC-4875-B57B-4B932E44B8E9Q51360207-79302228-3355-402E-B8D1-F6C061DEFF63Q51460171-AED95974-6164-4A74-A79E-76EFB893522DQ53273638-813D5A93-AEE6-4D3E-88B3-AE6562D67535Q55279510-490CE217-9659-4AE0-B054-6377FBC11CC1
P2860
Coronary in-stent restenosis - predictors, treatment and prevention.
description
2000 nî lūn-bûn
@nan
2000 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Coronary in-stent restenosis - predictors, treatment and prevention.
@ast
Coronary in-stent restenosis - predictors, treatment and prevention.
@en
Coronary in-stent restenosis - predictors, treatment and prevention.
@nl
type
label
Coronary in-stent restenosis - predictors, treatment and prevention.
@ast
Coronary in-stent restenosis - predictors, treatment and prevention.
@en
Coronary in-stent restenosis - predictors, treatment and prevention.
@nl
prefLabel
Coronary in-stent restenosis - predictors, treatment and prevention.
@ast
Coronary in-stent restenosis - predictors, treatment and prevention.
@en
Coronary in-stent restenosis - predictors, treatment and prevention.
@nl
P356
P1476
Coronary in-stent restenosis - predictors, treatment and prevention.
@en
P2093
P304
P356
10.1053/EUHJ.2000.2153
P577
2000-11-01T00:00:00Z